PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q92149

Tomoyuki HASEGAWA, et al.

Appln. No.: 10/561,214

Group Art Unit: 1624

Confirmation No.: 2252

Examiner: Susanna MOORE

Filed: August 29, 2006

For: 8-(3-PENTYLAMINO)-2-METHYL-3-(2-CHLORO-4-METHOXYPHENYL)-6,7-

DIHYDRO-5H-CYCLOPENTA[D]PYRAZOLO[1,5-A]PYRIMIDINE

METHANESULFONATE AS A CRF ANTAGONIST

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

U.S. Appln. No.: 10/561,214

Applicant notes the following:

1. U.S. Patent Nos. 6,194,574 and 6,495,686 correspond to WO 99/64422.

2. U.S. Patent Nos. 6,514,982 and 6,531,475 correspond to WO 00/27846.

3. U.S. Patent Nos. 6,348,466 and 6,723,721 correspond to WO 00/27850.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant submits the following explanation:

1. An English language abstract of HIMBERT et al submitted herewith constitutes a concise statement of relevance of HIMBERT et al.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 57,426

Hui C. Wauters

Attorney Docket No.: Q92149

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565
CUSTOMER NUMBER

Date: November 9, 2009

2